

Table 1- Supplement				
Demographics, baseline characteristics, treatment and clinical outcomes				
	SCI- n=29	SCI+ n=61	SCIinj+ n=87	*P value
Age, median (IQR)	83 (71-87)	79 (69-84.5)	86 (68-84)	0.295
Female, n (%)	18 (62.1)	31 (50.8)	50 (58)	0.317
NIHSS at presentation, median (IQR)	14 (9.5-16.5)	12 (7-16.5)	14 (10-17)	0.367
Baseline characteristics				
Hypertension, n (%)	15 (51.7)	42 (68.9)	59 (68.6)	0.115
Atrial Fibrillation, n (%)	10 (34.5)	21 (34.4)	32 (37.2)	0.996
Diabetes mellitus, n (%)	10 (34.5)	19 (31.1)	31 (36)	0.752
Dyslipidemia, n (%)	14 (48.3)	33 (54.1)	45 (52.3)	0.605
Current smoking, n (%)	3 (10.3)	8 (13.1)	11 (12.8)	0.708
Ischemic heart disease, n (%)	6 (20.7)	13 (21.3)	19 (22.1)	0.946
Prior Stroke/TIA, n (%)	10 (34.5)	13 (21.3)	21 (24.4)	0.181
Imaging characteristics at admission				
Tan collateral score, median (IQR)	2 (1-2)	2 (1-2)	2 (1-2)	0.598
ASPECTS, median (IQR)	9 (7.75-10)	8 (8-9)	8 (7-9)	0.481
ASPECTS-based striatocapsular involvement (SCAs+) ^{**} , n (%)	4 (13.8)	24 (39.3)	37 (43)	0.014
Treatment and clinical outcomes				
Onset to arrival time (minutes), mean (SD)	341(346)	357 (319)	361 (311)	0.849
IVT treatment, n (%)	8 (27.6)	12 (19.7)	15 (17.4)	0.399
Successful reperfusion (TICI: 2B-3), n (%)	26 (89.7)	50 (83.3)	74 (86)	0.429
Functional mRS day 90 (mRS=0-2), n (%)	11 (37.9)	23 (37.7)	25 (29.1)	0.984
mRS at 90d, mean (SD)	3.4 (2.1)	3.4 (2)	3.7 (1.9)	0.976
Mortality, n (%)	8 (27.6)	14 (23)	25 (29.1)	0.633
ICH, n (%)	3 (10.3)	9 (14.8)	22 (25.6)	0.565
SICH, n (%)	0 (0)	2 (3.3)	7 (8.1)	0.32
A-ICH, n (%)	3 (10.3)	6 (10)	13 (15.1)	0.96
SCI, Striatocapsular ischemia; SCIinj, Striatocapsular injury, NIHSS, National Institutes of Health Stroke Scale Score; ASPECTS, Alberta stroke program early CT score; IVT, intravenous thrombolytic; mRS, modified Rankin Scale; ICH, Intracranial hemorrhage; SICH Symptomatic ICH; A-ICH, asymptomatic ICH; TIA, Transient ischemic attack. *P value refers to main analysis comparing SCI+ and SCI- groups. ** ASPECTS-based striatocapsular involvement – Involvement of at least one striatocapsular region (caudate head, lentiform nucleus or internal capsule) on the ASPECTS score of admission NCCT.				

Table 2 - Supplement			
Thalamostriate vein ΔTTP (sec), mean (SD)			
Region	Region fate		P value
Caudate head	Viable	1.255 (2.0)	0.105
	Infarcted	1.958 (1.9)	
Caudate body	Viable	1.199 (1.7)	0.007
	Infarcted	2.459 (2.3)	
Lentiform	Viable	0.956 (2.1)	0.035
	Infarcted	1.904 (1.9)	
Internal capsule	Viable	1.292 (1.9)	0.134
	Infarcted	1.947 (2.0)	
TTP, Time to peak; ΔTTP = TTP ischemic hemisphere – TTP normal hemisphere			

Table 3 - Supplement			
Additional CTP parameters			
Mean (SD)	SCI- n= 29	SCI+ n= 61	P value
Total penumbra volume (cm ³)	93.2 (39.5)	111.9 (43.2)	0.059
Total core volume (cm ³)	7.3 (8.2)	18.8 (24)	0.018
rCBF - Caudate head	0.9 (0.45)	0.67 (0.3)	0.007
rCBV - Caudate head	0.99 (0.25)	0.84 (0.35)	0.061
rCBF - Lentiform nucleus	0.83 (0.61)	0.51 (0.25)	0.001
rCBV - Lentiform nucleus	0.99 (0.32)	0.77 (0.32)	0.004
SCI, Striatocapsular ischemia; rCBF, relative cerebral blood flow; rCBV, relative cerebral blood volume			

Table 4 - Supplement		
Multivariable Logistic Regression Analysis for Striatocapsular infarction		
	OR (95% CI), Infarct	P value
Delayed TTP Thalamostriate vein	1.511 (1.102-2.072)	0.010
Age	0.95 (0.907-0.995)	0.029
Sex (female)	1.692 (0.575-4.980)	0.339
Admission NCCT ASPECTS-based striatocapsular involvement*	2.895 (0.97-8.644)	0.057
Successful reperfusion (mTICI score ≥ 2B)	1.816 (0.338-9.754)	0.486
Good collaterals pre CTA (Tan score ≥ 2)	1.766 (0.556-5.606)	0.335
IVT	1.325 (0.381-4.617)	0.658
Striatocapsular infarction = infarction in either Caudate head, Caudate body, Lentiform or Internal Capsule; TTP, Time to peak; IVT, intravenous thrombolytic		
* ASPECTS-based striatocapsular involvement – Involvement of at least one striatocapsular region (caudate head, lentiform nucleus or internal capsule) on the ASPECTS score of admission NCCT.		